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Abstract
Background: The number of Salmonella strains with reduced susceptibility to fluoroquinolones
has increased during recent years in many countries, threatening the value of this antimicrobial
group in the treatment of severe salmonella infections.
Methods: We analyzed the in vitro activities of ciprofloxacin and 10 additional fluoroquinolones
against 816 Salmonella strains collected from Finnish patients between 1995 and 2003. Special
attention was focused on the efficacy of newer fluoroquinolones against the Salmonella strains with
reduced ciprofloxacin susceptibility.
Results: The isolates represented 119 different serotypes. Of all 816 Salmonella strains, 3 (0.4%)
were resistant to ciprofloxacin (MIC ≥ 4 µg/ml), 232 (28.4%) showed reduced susceptibility to
ciprofloxacin (MIC ≥ 0.125 – 2 µg/ml), and 581 (71.2%) were ciprofloxacin-susceptible. The MIC50
and MIC90 values of ciprofloxacin for these strains were 0.032 and 0.25 µg/ml, respectively, being
lower than those of the other fluoroquinolone compounds presently on market in Finland
(ofloxacin, norfloxacin, levofloxacin, and moxifloxacin). For two newer quinolones, clinafloxacin
and sitafloxacin, the MIC50 and MIC90 values were lowest, both 0.016 and 0.064 µg/ml, respectively.
Moreover, clinafloxacin and sitafloxacin exhibited the lowest MIC50 and MIC90 values, 0.064 and
0.125 µg/ml, against the 235 Salmonella strains with reduced susceptibility and strains fully resistant
to ciprofloxacin.
Conclusion: Among the registered fluoroquinolones in Finland, ciprofloxacin still appears to be
the most effective drug for the treatment salmonella infections. Among the newer preparations,
both clinafloxacin and sitafloxacin are promising based on in vitro studies, especially for strains
showing reduced ciprofloxacin susceptibility. Their efficacy, however, has not been demonstrated
in clinical investigations.
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Background
Fluoroquinolones generally have a good in vitro and clin-
ical activity against isolates of the Salmonella species [1].
Although the Clinical and Laboratory Standards Institute
(CLSI; formerly the National Committee for Clinical Lab-
oratory Standards, NCCLS) guidelines recommend the
MICs of ≤1 and ≥4 µg/ml as respective breakpoints of sus-
ceptibility and resistance to ciprofloxacin [2], it is now
commonly accepted that Salmonella  isolates with MICs
between ≥0.125 and 2 µg/ml are characterized by reduced
susceptibility i.e. low-level resistance to fluoroquinolo-
nes. The selection of MICs ≥0.125 µg/ml as a breakpoint
of reduced ciprofloxacin susceptibility is justified based
on histogram and scatterblot analyses combined with
sequencing data [3-8]. This selection is further supported
by reports on several treatment failures with ciprofloxacin
and other fluoroquinolones in patients with infections
caused by Salmonella strains showing reduced susceptibil-
ity to fluoroquinolones [9-17].
It is of concern that in recent years, the number of Salmo-
nella isolates with reduced fluoroquinolone susceptibility
has increased in many countries, including countries of
the European Union [6,18-21]. In Finland, reduced fluor-
oquinolone susceptibility emerged between 1995 and
1997 among Salmonella isolates of domestic origin [21],
and a significant increase in the annual proportion of
reduced fluoroquinolone susceptibility was observed
between 1995 and 1999 among both the domestic and
foreign isolates [5].
Several fluoroquinolone preparations are on market all
over the world, while a number of new compounds are
presently being developed or undergoing clinical studies.
The purpose of the present study was to determine the in
vitro activities of various older and newer fluoroquinolo-
nes towards the Salmonella species, focusing special atten-
tion on the isolates with reduced ciprofloxacin
susceptibility. In so doing, we determined the susceptibil-
ities of 816 epidemiologically unrelated Salmonella iso-
lates to ciprofloxacin and 10 additional fluoroquinolones
including two novel extended-spectrum compounds: clin-
afloxacin and sitafloxacin.
Methods
Salmonella strains
Antimicrobial susceptibility of Salmonella enterica isolates
has been surveyed in the National Public Health Institute,
Finland, since 1995 by analyzing yearly 200–400 strains
collected from Finnish patients seeking medical assistance
for gastroenteritis. Starting in January each year, we con-
secutively collect 100–200 foreign strains and 100–200
domestic (i.e., Finnish) strains for susceptibility testing.
An isolate is designated as of foreign origin, if the patient
has reported travel abroad during one month before the
specimen day. All other isolates are designated as of
domestic origin. Epidemiological information regarding
potential travelling and the travel destination is collected
from the forms which accompany each isolate sent to the
Enteric Bacteria Laboratory of the National Public Health
Institute, Helsinki, which serves as the National Salmo-
nella Reference Centre in Finland.
We included in this study a total of 816 clinical Salmonella
strains collected between 1995 and 2003 during the
annual surveys. All strains were isolated from stool. Of
these strains, 365 were designated as of domestic origin
and 451 as of foreign origin. The strains were considered
to be epidemiologically unrelated based on their recovery
from distinct sources. For each Salmonella outbreak recog-
nized, only one isolate representing the epidemic strain
was included. The Salmonella collection consisted of 119
different serotypes. All strains belonged to non-typhoidal
Salmonella enterica. The most prevalent serotypes were S.
Enteritidis, S. Typhimurium, and S. Hadar, accounting for
27.2%, 19.0%, and 7.1% of the isolates, respectively.
Susceptibility testing
The minimum inhibitory concentrations (MIC) of the iso-
lates were determined by the standard agar plate dilution
method according to the NCCLS guidelines [22]. Mueller-
Hinton II agar (BBL, Becton Dickinson and Company,
Cockeysville, Md.) was used as the culture medium. Alto-
gether 11 fluoroquinolone compounds were analyzed.
Reagent powder of each of these agents was provided by
its manufactorer: ciprofloxacin (Bayer, Wuppertal, Ger-
many), clinafloxacin (Pfizer, Ann Arbor, MI, Unites
States), enrofloxacin (Bayer, Elberfeld, Germany), gati-
floxacin (Grunenthal BHBH, Aachen, Germany), gemi-
floxacin (GlaxoSmithKline, Worthing, United Kingdom),
levofloxacin (Hoechst Marion Roussel, Romainville
Cedex, France), lomefloxacin (Sigma, St. Luis, MO,
United States), moxifloxacin (Bayer, Wuppertal, Ger-
many), norfloxacin and ofloxacin (Sigma, Steinheim,
Germany), and sitafloxacin (Daiichi Pharmaceuticals,
Tokyo, Japan). The Salmonella isolates were also tested for
susceptibility to nalidixic acid.
Of the fluoroquinolone compounds analyzed, cipro-
floxacin, ofloxacin, norfloxacin, levofloxacin, and moxi-
floxacin are presently on market in Finland.
Staphylococcus aureus ATCC 29213, Escherichia coli ATCC
25922, E. coli ATCC 35218, and Pseudomonas aeruginosa
ATCC 27853 were used as controls in susceptibility
testing.Annals of Clinical Microbiology and Antimicrobials 2005, 4:12 http://www.ann-clinmicrob.com/content/4/1/12
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Data analysis
The susceptibility data were analyzed using the
WHONET5 computer program (available from http://
www.who.int/drugresistance/whonetsoftware/en/).
Results
Of all 816 Salmonella strains, 3 (0.4%) were resistant to
ciprofloxacin (MIC ≥ 4 µg/ml), 232 (28.4%) showed
reduced susceptibility to ciprofloxacin (MIC ≥ 0.125 – 2
µg/ml), and 581 (71.2%) were ciprofloxacin-susceptible.
Of the 451 foreign Salmonella strains, 2 (0.4%) were cip-
rofloxacin-resistant and 193 (42.8%) showed reduced
susceptibility to ciprofloxacin. Of the 365 domestic Salmo-
nella strains, 1 (0.3%) was ciprofloxacin-resistant and 39
(10.7%) showed reduced susceptibility to ciprofloxacin.
For all 816 strains, the MIC50 and MIC90 values of cipro-
floxacin were 0.032 and 0.25 µg/ml, respectively (Table
1). For ofloxacin, levofloxacin, norfloxacin, and moxi-
floxacin, the MIC50  values varied between 0.064 and
0.125 µg/ml; and the MIC90 values, between 0.5 and 1 µg/
ml. The MIC50 and MIC90 values of enrofloxacin, lome-
floxacin, gatifloxacin, and gemifloxacin were similar to or
higher than those of ciprofloxacin. For both clinafloxacin
and sitafloxacin, the MIC50 and MIC90 values were lower
than for the other agents tested, 0.016 and 0.064 µg/ml,
respectively. The histograms illustrating the MICs of the
fluoroquinolones studied are presented in Figure 1. The
MIC50 and MIC90 values of nalidixic acid were 4 and 512
µg/ml, respectively (range, <0.5 to >512 µg/ml).
The most prevalent serotypes among the 235 Salmonella
strains with reduced susceptibility or resistance to cipro-
floxacin were S. Hadar, S. Enteritidis, and S. Virchow
accounting for 22.6%, 20.9%, and 12.3% of the strains,
respectively. For these 235 strains, the MIC50 values of
ofloxacin, levofloxacin, norfloxacin and moxifloxacin var-
ied between 0.5 and 1 µg/ml; and the MIC90 value was 1
µg/ml for all (Table 2). The MIC50 and MIC90 values were
lowest, 0.064 and 0.125 µg/ml, for both clinafloxacin and
sitafloxacin. For the additional 4 fluoroquinolones exam-
ined, the MIC50 varied between 0.25 and 2 µg/ml; and the
MIC90 values, between 0.5 and 2 µg/ml. The MIC50 and
MIC90 values of nalidixic acid for these strains were 512
and >512 µg/ml, respectively (range, 4 to >512 µg/ml).
The scattergrams correlating the MICs of ciprofloxacin to
those of clinafloxacin, levofloxacin, moxifloxacin, nor-
floxacin, ofloxacin, and sitafloxacin for the 816 Salmonella
strains are presented in Figure 2. These pictures illustrate
that there is a distinct correlation between the cipro-
floxacin susceptibility and the susceptibility to other fluo-
roquinolones. The MICs of levofloxacin, moxifloxacin,
norfloxacin, and ofloxacin were generally higher than
those of ciprofloxacin, but for each, the fully susceptible
population was separate from the population with
reduced susceptibility. Of the 232 Salmonella strains with
reduced ciprofloxacin susceptibility, the MICs of lev-
oxacin, moxifloxacin, norfloxacin, and ofloxacin were 1
or 2 dilution steps higher than those of ciprofloxacin. In
contrast, the MICs of clinafloxacin and sitafloxacin were
generally 2 dilution steps lower than those of
ciprofloxacin.
Discussion
Of all 816 Salmonella strains included in the present study,
28.8% showed resistance or reduced susceptibility to cip-
rofloxacin. The MIC50 and MIC90 values of ciprofloxacin
for these isolates were 0.032 and 0.25 µg/ml, respectively,
being similar to or lower than those of all older fluoroqui-
nolone compounds studied. Thus, we show that cipro-
floxacin still is the most effective fluoroquinolone drug
registered in Finland for the treatment of salmonellosis. In
the entire Salmonella collection, the MIC50 and MIC90 val-
ues were lowest for two new quinolones: clinafloxacin
and sitafloxacin. Moreover, clinafloxacin and sitafloxacin
exhibited the lowest MIC50 and MIC90 values for the 235
ciprofloxacin-resistant Salmonella strains or strains show-
ing reduced ciprofloxacin susceptibility. Based on these in
vitro results, both clinafloxacin and sitafloxacin appear
promising drugs for the treatment of salmonella infec-
tions, but their efficacy has not been demonstrated in clin-
ical investigations.
The introduction of fluoroquinolones in the 1980's had
an almost revolutionary effect on the treatment of salmo-
nellosis, since they offered an effective per oral alternative
to treat clinical infections as well as to eradicate long-term
carriage. So far, the emergence and rapid increase of
reduced fluoroquinolone susceptibility in non-typhoidal
salmonellas has not led to major consequences, since
these microbes characteristically cause gastroenteritis, for
which antimicrobial treatment is not always indicated.
The situation is totally different in invasive salmonella
infections, in which administration of an effective antimi-
crobial agent is vitally important. If such an infection is
caused by a Salmonella  strain with reduced fluoroqui-
nolone susceptibility, treatment with a fluoroquinolone
compound may not be a safe alternative. There are several
reports showing that the use of fluoroquinolones in infec-
tions caused by Salmonella isolates with reduced suscepti-
bility may lead to treatment failures [6-17]. The majority
of the cases have involved Salmonella enterica serotype
Typhi [8,10-12,15]. In non-typhoidal salmonellosis, the
causative strain has often been initially fully susceptible,
but after fluoroquinolone treatment failure, the MICs for
these strains have been ≥0.125 µg/ml [13,14,17].
Clinafloxacin and sitafloxacin are the most interesting
fluoroquinolone compounds studied here, since earlierAnnals of Clinical Microbiology and Antimicrobials 2005, 4:12 http://www.ann-clinmicrob.com/content/4/1/12
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MIC histograms of fluoroquinolones Figure 1
MIC histograms of fluoroquinolones. Minimum inhibitory concentration (MIC) histograms of 11 fluoroquinolones against 
816 Salmonella strains collected from Finnish patients between January 1995 and January 2003.
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data on their activity against the Salmonella species are
limited. We found only one previous study, in which the
in vitro activity of sitafloxacin against 326 Salmonella iso-
lates was tested, with a finding that its activity was equal
to or slightly better than that of ciprofloxacin [23].
One of the main purposes of the present study was to ana-
lyze the in vitro activities of these two novel fluoroqui-
nolone compounds towards Salmonella  isolates with
reduced ciprofloxacin susceptibility. Our results show that
the MIC50 and MIC90 of clinafloxacin and sitafloxacin
against these strains were generally 2 dilution steps lower
than those of ciprofloxacin and even 4 to 5 dilution steps
lower than some of the older fluoroquinolones. Neverthe-
less, this does not necessarily mean that they should have
a superior in vivo activity. The fluoroquinolone antimi-
crobial group is characterized by cross resistance, indicat-
ing that when a bacterial isolate is resistant to one
fluoroquinolone, it is also resistant to other members of
the same group [24].
The development of fluoroquinolone resistance most
commonly involves a mutation in the quinolone resist-
ance determining region (QRDR) of the gyrA gene
[4,5,14,25,26]. One single point mutation usually leads
to nalidixic acid resistance and reduced fluoroquinolone
Table 1: MICs of 11 fluoroquinolones for 816 non-typhoidal strains of Salmonella enterica isolated from Finnish patients between 1995 
and 2003
MIC (µg/ml)
Fluoroquinolone Number of isolates MIC50 MIC90 Range
Ciprofloxacin 816 0.032 0.25 0.008 – 16
Clinafloxacin 816 0.016 0.064 0.002 – 2
Enrofloxacin 808 0.064 0.5 0.032 – >32
Gatifloxacin 816 0.032 0.25 0.002 – 8
Gemifloxacin 815 0.032 0.25 0.002 – >16
Levofloxacin 808 0.064 0.5 ≤0.008 – 16
Lomefloxacin 807 0.25 2 0.064 – >32
Moxifloxacin 816 0.125 0.5 0.008 – >16
Norfloxacin 816 0.125 1 0.016 – >32
Ofloxacin 816 0.125 1 0.016 – >16
Sitafloxacin 816 0.016 0.064 0.002 – 2
Table 2: MICs of 11 fluoroquinolones for 235 non-typhoidal strains of Salmonella enterica with reduced ciprofloxacin susceptibility1 or 
ciprofloxacin resistance2 isolated from Finnish patients between 1995 and 2003
MIC (µg/ml)
Fluoroquinolone Number of isolates MIC50 MIC90 Range
Ciprofloxacin 235 0.25 0.5 0.125 – 16
Clinafloxacin 235 0.064 0.125 0.008 – 2
Enrofloxacin 233 0.5 1 0.032 – >32
Gatifloxacin 235 0.25 0.5 0.032 – 8
Gemifloxacin 235 0.25 0.5 0.064 – >16
Levofloxacin 233 0.5 1 0.064 – 16
Lomefloxacin 232 2 2 0.25 – >32
Moxifloxacin 235 0.5 1 0.25 – >16
Norfloxacin 235 1 1 0.25 – >32
Ofloxacin 235 1 1 0.125 – >16
Sitafloxacin 235 0.064 0.125 0.016 – 2
1Ciprofloxacin MIC ≥0.125 – 2 µg/ml
2Ciprofloxacin MIC ≥4 µg/mlAnnals of Clinical Microbiology and Antimicrobials 2005, 4:12 http://www.ann-clinmicrob.com/content/4/1/12
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Scattergrams correlating the MICs of ciprofloxacin to those of other fluoroquinolones Figure 2
Scattergrams correlating the MICs of ciprofloxacin to those of other fluoroquinolones. Scattergrams for 816 Sal-
monella strains correlating the minimum inhibitory concentrations (MIC) of ciprofloxacin to those of clinafloxacin, levofloxacin, 
moxifloxacin, norfloxacin, ofloxacin, and sitafloxacin. The numbers within the graphs indicate the numbers of Salmonella strains. 
The vertical solid lines indicate the Clinical and Laboratory Standards Istitute (CLSI) breakpoint recommendations for suscepti-
bility and resistance, respectively, to ciprofloxacin (MIC ≤1 and ≥4 µg/ml); and the vertical dashed lines, the breakpoint for 
reduced susceptibility (MIC ≥0.125 µg/ml). The horizontal solid lines indicate the respective CLSI breakpoint recommendations 
to those fluoroquinolones for which such recommendations are available: ofloxacin (MIC ≤2 and ≥8 µg/ml); norfloxacin (MIC 
≤4 and ≥16 µg/ml); and levofloxacin (MIC ≤2 and ≥8 µg/ml).
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susceptibility, while additional mutations or accumula-
tion of several resistance mechanisms are needed to pro-
duce high-level fluoroquinolone resistance. On this basis,
one can assume that in the majority of the Salmonella
strains with reduced fluoroquinolone susceptibility ana-
lyzed here, quinolone resistance is associated with one
point mutation. Based on their low MIC values, both clin-
afloxacin and sitafloxacin may potentially have useful
clinical activity against Salmonella  strains with a single
mutation in the gyrA gene. It must be borne in mind,
however, that having undergone one point mutation,
these isolates are potentially inclined to a second muta-
tion, leading to higher MIC values. Thus, it is probable
that resistance will develop during fluoroquinolone treat-
ment also against these newer quinolones, despite their
initially low MIC values.
It is also of note that the clinical relevance of various MIC
values of clinafloxacin and sitafloxacin is not known. Fur-
ther, no breakpoins of resistance or susceptibility have
been given by the CLSI for these newer fluoroquinolone
compounds. Neither do we know anything about their
potential breakpoints for reduced fluoroquinolone
susceptibility.
Many previous studies have focused on in vitro efficacy of
clinafloxacin and sitafloxacin on microbes other than sal-
monellas [23,27-29]. In these studies, the two new fluor-
oquinolones have had a better activity than the older
preparations towards a variety of bacterial species, even
including the ciprofloxacin-resistant strains. For example,
clinafloxacin exhibited greater activity than older fluoro-
quinolones against ciprofloxacin-resistant Klebsiella pneu-
moniae  and  Enterobacter aerogenes isolates [27], and
sitafloxacin proved superior to the others against
ciprofloxacin-resistant isolates of several enterobacterial
species [23]. Moreover, a number of studies have demon-
strated the clinical efficacy of clinafloxacin in the treat-
ment of systemic infections, including severe skin and soft
tissue diseases and infective endocarditis, and in empirical
therapy of febrile granulocytopenic patients [30-33].
These data are encouraging and suggest that the clinical
efficacy of these novel fluoroquinolones should be tested
also in salmonellosis.
The possible clinical usefulness of the two newer quinolo-
nes against Salmonella strains will also depend on the lev-
els of the drug reaching the infecting organism. It has been
shown in previous studies that in general, newer fluoro-
quinolones have equal or greater bioavailability com-
pared with ciprofloxacin, which varies between 55 to 88%
[34]. Limited data suggest that at least 70% of sitafloxacin
is absorbed after an oral dose [35]. In one study, the
absolute bioavailability of orally administered clina-
floxacin was approximately 90% [36]. Thus, it is expected
that these drugs will prove effective also in the oral treat-
ment of salmonellosis.
Conclusion
Among the registered fluoroquinolone compounds in
Finland, ciprofloxacin still appears to be the most effective
drug for the treatment salmonella infections. Among the
newer preparations, both clinafloxacin and sitafloxacin
are promising based on in vitro studies, since they exhib-
ited the lowest MIC50 and MIC90 values for all Salmonella
isolates as well as for those with reduced fluoroquinolone
susceptibility.
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